Carcinoid/Neuroendocrine Cancer Specialist Takes Leave of Absence from Medical Practice

October 15, 2016

Dr. Richard R.P. Warner, Director of the Center for Carcinoid and Neuroendocrine Tumors at Mount Sinai Hospital, has announced that he is taking a medical leave of absence from his practice at Mount Sinai in New York City, as of November 1, 2016. Read more


Stanford Health Care in California Launches Neuroendocrine Tumor Multidisciplinary Program

August 14, 2016

A new multidisciplinary Neuroendocrine Cancer center at Stanford Health Care in California has been established to improve the standard of care for NET patients and to advance the study of these rare diseases. Pamela Kunz, MD, is the Medical Director…


Carcinoid Cancer Foundation Announces Appointment of Edward M. Wolin, MD as Co-Medical Director and Board Member

June 24, 2016

Edward M. Wolin, MD, an internationally renowned neuroendocrine cancer specialist and medical oncologist, has been named Co-Medical Director and Board member of the Carcinoid Cancer Foundation (CCF) in White Plains, New York.  Dr. Wolin is Director


Ipsen Partners with CCF and Self Care Catalysts to Provide Free Support App for Neuroendocrine Tumor Patients

April 6, 2016

Ipsen Biopharmaceuticals has partnered with the Carcinoid Cancer Foundation and Self Care Catalysts to provide a digital patient support tool known as the Carcinoid NETs Health Storylines mobile and web application. Sponsored in part by Ipsen, the…


Lexicon Pharmaceuticals Submits New Drug Application for Telotristat Etiprate

April 3, 2016

Lexicon Pharmaceuticals has submitted a new drug application to the US Food and Drug Administration (FDA) for Telotristat Etiprate for the treatment of carcinoid syndrome.

For patients with carcinoid syndrome who are no longer responding to the current…


Breaking News about PRRT

March 23, 2016

Advanced Accelerator Applications (AAA) announced  on March 23, 2016 that the company has initiated an expanded access program (EAP) in the United States for the investigational product, Lutathera. Through the program Lutathera is being made available…


Finding an Outlet in the Face of Rare Cancers by Diane Reidy Lagunes, MD

March 16, 2016

Carcinoid/neuroendocrine cancer specialist Dr. Diane Reidy Lagunes, medical oncologist at Memorial Sloan Kettering Cancer Center in New York City, explains how her patients inspire her as a physician and why she participates in Cycle for Survival


Rare Disease Day 2016

February 29, 2016

February 29, 2016 is Rare Disease Day, an annual, international advocacy day to bring widespread recognition of rare diseases as a global health challenge. The Carcinoid Cancer Foundation is proud to be a Rare Disease Day Partner.  Learn more here: …


FDA Approves Afinitor for Gastrointestinal and Lung Neuroendocrine Tumors

February 26, 2016

Breaking News!  Afinitor Receives FDA Approval in GI and Lung NETs.…/fda-approves-new-indication-nova…


Neuroendocrine Cancer Experts Hold Inaugural Summit in Colorado, February 25-26, 2016

February 24, 2016

Over 30 neuroendocrine tumor (NET) expert physicians and researchers from the United States and Europe will come together for a two-day summit, February 25 and 26, 2016, in Beaver Creek, Colorado, where they will share knowledge and experience that …